CELZ - Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings Inc Logo

CELZ - Creative Medical Technology Holdings Inc

https://www.creativemedicaltechnology.com
Recent News
Powered by Alpha Vantage
Neutral
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain
GlobeNewswire • 1 month ago • score: 0.14
PHOENIX, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Creative Medical Technology Holdings, Inc. ( NASDAQ: CELZ ) , a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track ...
Bullish
Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells
GlobeNewswire • 1 month, 4 weeks ago • score: 0.26
PHOENIX, July 17, 2025 ( GLOBE NEWSWIRE ) -- Creative Medical Technology Holdings, Inc. ( NASDAQ: CELZ ) ( "Creative Medical" or the "Company" ) , a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the ...
Bullish
Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
GlobeNewswire • 2 months ago • score: 0.29
PHOENIX, July 11, 2025 ( GLOBE NEWSWIRE ) -- Creative Medical Technology Holdings, Inc. ( NASDAQ: CELZ ) ( "Creative Medical" or the "Company" ) , a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company is headquartered in Phoenix, Arizona.

52W High
$6.90
52W Low
$1.69
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
5.34
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.46
EV/Revenue (<3 favorable)
332.91
P/S (TTM) (<3 favorable)
1423.59
P/B (<3 favorable)
1.25
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
1.37%
Institutions (25–75% balanced)
8.03%
Shares Outstanding
2,580,500
Float
2,179,700
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
6,000
Gross Profit (TTM)
3,600
EPS (TTM)
-3.13
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-986.57%
ROE (TTM) (>15% strong)
-0.80%
EPS YoY (Quarterly) (>10% good)
3.59
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—